The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
复制标题
DOI：
10.1007/s10549-018-4745-7
复制
发表时间：
2018-07
影响因子：
3.8
通讯作者：
Khoury T
中科院分区：
文献类型：
--
作者：
Li Y;Opyrchal M;Yao S;Peng X;Yan L;Jabbour H;Khoury T
本研究的目的是探讨PD-L1表达和肿瘤浸润淋巴细胞（TIL）在HER 2+乳腺癌（BC）中的预后意义。在1996年至2013年期间收集了HER 2 + BC病例（n=191）。用两种PD-L1抗体克隆（28-8和22 C3）对组织微阵列（TMA）载玻片进行染色，并对阳性膜染色的百分比进行评分。还使用百分比量表对完整切片的TIL进行评分。克隆28-8在25.7%的病例中在≥1%的肿瘤细胞中表达，而克隆22 C3在11.5%的病例中在≥1%的肿瘤细胞中表达。在多变量分析中，肿瘤中PD-L1（克隆28-8）的高表达与肿瘤复发风险较低相关，HR为0.4（p=0.033）。在HR为0.35的所有患者中，较高水平的TIL（>15%）预测更好的总生存期（OS）（p=0.0046）。在接受基于曲妥珠单抗的辅助化疗的患者组中，TIL中较低的PD-L1（克隆28-8）表达与肿瘤复发相关（p=0.034）。在接受基于非曲妥珠单抗的辅助化疗的患者组中，肿瘤中较低的TIL和较低的PD-L1（克隆28-8）表达与肿瘤复发相关，具有边缘统计学显著性，分别为p=0.064和0.083。在接受基于曲妥珠单抗的辅助化疗的患者组中，PD-L1或TIL对预测5年生存率无统计学意义。在接受非曲妥珠单抗辅助化疗的患者组中，低TIL（p=0.009）与5年疾病死亡相关。我们得出结论，PD-L1可能在HER 2 + BCs中具有预后意义。
The purpose of the study is to investigate the prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes (TILs) in HER2+ breast cancer (BC). HER2+ BC cases (n=191) were collected between 1996 and 2013. Tissue microarray (TMA) slides were stained with two clones of PD-L1 antibodies (28-8 and 22C3) and the percentage of positive membranous staining was scored. TILs of the full sections were also scored using percentage scale. Clone 28-8 had expression in ≥1% of the tumor cells in 25.7% of the cases, while clone 22C3 in ≥1% of the tumor cells was expressed in 11.5% of the cases. In the multivariate analysis, higher expression of PD-L1 (clone 28-8) in tumor correlated with lower risk of tumor recurrence, with HR of 0.4 (p=0.033). Higher level of TILs (>15%) predicts better overall survival (OS) in all patients with HR of 0.35 (p=0.0046). In the group of patients who were treated with trastuzumab-based adjuvant chemotherapy, lower PD-L1 (clone 28-8) expression in TILs correlated with tumor recurrence (p=0.034). In the group of patients who were treated with non-trastuzumab-based adjuvant chemotherapy, lower TILs and lower PD-L1 (clone 28-8) expression in tumor had borderline statistical significance in association with tumor recurrence, p=0.064 and 0.083, respectively. In the group of patients who were treated with trastuzumab-based adjuvant chemotherapy, PD-L1 or TILs was not statistically significant to predict 5-year survival. In the group of patients who were treated with non-trastuzumab-based adjuvant chemotherapy, low TILs (p=0.009) correlated with 5-year death due to disease. We conclude that PD-L1 may have prognostic significance in HER2+ BCs.
登录
查看更多内容
DOI：
10.1016/s1470-2045(16)30631-3
发表时间：
2017-01
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Luen SJ;Salgado R;Fox S;Savas P;Eng-Wong J;Clark E;Kiermaier A;Swain SM;Baselga J;Michiels S;Loi S
通讯作者：
Loi S
影响因子：
45.3
作者：
Adams, Sylvia;Gray, Robert J.;Badve, Sunil S.
通讯作者：
Badve, Sunil S.
影响因子：
3.3
作者：
Baptista, Mauricio Z.;Sarian, Luis Otavio;Vassal, Jose
通讯作者：
Vassal, Jose
影响因子：
7
作者：
Mittal, Deepak;Gubin, Matthew M.;Schreiber, Robert D.;Smyth, Mark J.
通讯作者：
Smyth, Mark J.
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM